{"id":"sodium-valproate-with-clozapine","safety":{"commonSideEffects":[{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Metabolic syndrome"},{"rate":null,"effect":"Tremor"},{"rate":"0.5-1%","effect":"Agranulocytosis (clozapine-related)"},{"rate":null,"effect":"Orthostatic hypotension"},{"rate":null,"effect":"Anticholinergic effects"}]},"_chembl":{"chemblId":"CHEMBL433","moleculeType":"Small molecule","molecularWeight":"166.20"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sodium valproate enhances GABAergic neurotransmission and inhibits histone deacetylases, providing mood-stabilizing and neuroprotective effects. Clozapine is a second-generation antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. Together, they target multiple neurotransmitter systems implicated in psychotic and mood disorders, potentially improving efficacy in treatment-resistant conditions.","oneSentence":"This combination pairs sodium valproate (a histone deacetylase inhibitor and GABA enhancer) with clozapine (an atypical antipsychotic) to provide synergistic effects on mood stabilization and antipsychotic activity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:08:43.479Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia (treatment-resistant or acute exacerbation)"},{"name":"Bipolar disorder with psychotic features"}]},"trialDetails":[{"nctId":"NCT05603104","phase":"PHASE3","title":"Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-04-27","conditions":"Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression","enrollment":1254},{"nctId":"NCT03652974","phase":"PHASE4","title":"Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2018-09-06","conditions":"Schizophrenia","enrollment":145},{"nctId":"NCT02926976","phase":"NA","title":"The Optimal Treatment for Treatment-resistant Schizophrenia","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2016-11","conditions":"Schizophrenia","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Valproate"],"phase":"marketed","status":"active","brandName":"sodium valproate with Clozapine","genericName":"sodium valproate with Clozapine","companyName":"Shanghai Mental Health Center","companyId":"shanghai-mental-health-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination pairs sodium valproate (a histone deacetylase inhibitor and GABA enhancer) with clozapine (an atypical antipsychotic) to provide synergistic effects on mood stabilization and antipsychotic activity. Used for Schizophrenia (treatment-resistant or acute exacerbation), Bipolar disorder with psychotic features.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}